UNSPSC 51384202: Loxoprofen

This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3583H0GZAP. European Medicines Agency schedules Loxoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08609MIG. Loxoprofen generally arises in the molecular formula C15H18O3.

UNSPSC 51384202 Loxoprofen, a Commodity code, covers pharmaceutical products that state and local governments procure for public health and emergency response programs. Recent solicitations under this code show minimal direct purchasing of loxoprofen; instead, jurisdictions are acquiring related naloxone and drug deactivation systems for community health initiatives and overdose response. The issuing bodies soliciting under this code include county health departments and community health authorities managing opioid crisis interventions and emergency pharmaceutical stockpiles. Procurement is typically conducted through competitive sealed bidding (IFB) with multi-year contracts and renewal options.

Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The solicitation required electronic bid submission, included E-Verify and drug-free workplace compliance requirements, carried insurance and liability mandates, and offered a two-year initial term with a one-year renewal option. The bid deadline was July 26, 2023. Geographic activity under the code remains concentrated in Florida based on recent public opportunities, though the small sample size and the apparent mismatch between the code's nominal scope (loxoprofen, a nonsteroidal anti-inflammatory) and actual purchasing (naloxone and harm-reduction systems) suggests this code sees limited state and local procurement activity aligned with its stated definition.